Objective:To investigate the prognostic value and safety of thoracic radiotherapy in patients with synchronous oligometastatic, driver gene-negative non-small cell lung cancer (NSCLC) receiving immune checkpoint inhibitors (ICIs) as first-line treatment.Methods:Data were retrospectively collected from 55 patients diagnosed with synchronous oligometastatic, driver gene-negative NSCLC who received first-line ICIs from January 2017 to March 2022. These patients were categorized into two groups based on the administration of thoracic radiotherapy: the thoracic radiotherapy group ( n = 27) and the non-thoracic radiotherapy group ( n = 28). Comparative analyses were conducted to evaluate survival outcomes and safety profiles between the two groups. Results:Among the 55 patients, 27 (49.1%) received thoracic radiotherapy. The median follow-up time was 37.0 months (2.2-76.7 months). Patients in the thoracic radiotherapy group exhibited significantly improved median overall survival (OS: 53.4 vs. 21.3 months, P = 0.049) and median progression-free survival (PFS: 13.6 vs. 8.3 months, χ2=4.11, P = 0.043) compared to those in the non-thoracic radiotherapy group. Multivariate Cox regression analysis identified thoracic radiotherapy as an independent prognostic factor for OS ( HR = 0.39, 95% CI: 0.17-0.90, P = 0.027) and PFS ( HR = 0.53, 95% CI: 0.28-0.99, P = 0.046). The most common grade 3 or higher toxicity was bone marrow suppression, occurring in seven patients (12.7%). There was no significant difference between both groups in the incidence of grade 3 or higher treatment-related adverse events, including pneumonitis. Conclusion:In patients with driver gene-negative, synchronous oligometastatic NSCLC, first-line immunotherapy combined with thoracic radiotherapy may improve survival outcomes without increasing the incidence of severe treatment-related adverse events. Further large-scale, randomized prospective trials are needed to verify the findings of this study.

Objective:To investigate the death risk of gastric cancer patients with different primary sites.Methods:The data of 35 263 gastric cancer patients from 2004 to 2015 were extracted from of the National Cancer Institute the Surveillance, Epidemiology, and End Results (SEER) database. According to the recorded causes of death, the treatment outcomes were classified into 3 categories: death from gastric cancer, death from non-gastric cancer and others. All included patients were grouped by age, gender, race, region, and marital status. Statistical analysis was conducted by using R 4.2.1 software to compare the composition of patients with different treatment outcomes at 3-year, 5-year, and 10-year in each factor subgroup. Univariate Fine-Gray competing model was used to analyze the cumulative incidence of death at 3-year, 5-year, and 10-year in gastric cancer patients with different primary sites. The 5 factors mentioned above were included in the multivariate Fine-Gray competing model to analyze the factors influencing the risk of death from gastric cancer in the entire population at 3-year, 5-year, and 10-year and in gastric cancer patients with different primary sites for 10 years in each factor subgroup after adjusting for demographic differences.Results:Among the entire population, there were 13 392 cases of cardia, 2 198 cases of gastric fundus, 4 510 cases of gastric body, 8 394 cases of antrum, 1 154 cases of pylorus, 3 633 cases of lesser curvature, and 1,982 cases of greater curvature. There were statistically significant differences in the composition of 3-year, 5-year, and 10-year treatment outcomes including death from gastric cancer, non-gastric cancer and other outcomes of gastric cancer patients stratified by different age, gender, race, region, marital status, and primary sites of tumors among subgroups (all P < 0.001). Univariate Fine-Gray model analysis showed that the cumulative incidence of death from gastric cancer was 29.0%, 30.9% and 31.6%, respectively at 3-year,5-year and 10-year after the confirmed diagnosis in gastric cancer patients with primary sites in the cardia, which was all lower than that in those with primary site in the gastric fundus (44.5%, 46.8%, 47.7%), the gastric body (49.1%, 46.8%, 53.5%), the antrum (51.4%, 54.7%, 56.1%), the pylorus (53.6%, 57.8%, 59.8%), the lesser curvature (44.4%, 48.4%, 50.0%), and the greater curvature (42.4%, 45.0%, 46.4%). Multivariate Fine-Gray model analysis showed that the 3-year, 5-year, and 10-year mortality risks of gastric cancer patients with the primary site in the cardia were all lower than those of patients with the primary sites in other locations (all HR > 1, P < 0.001); taking the 10-year death from gastric cancer as an example, the death risks of gastric cancer patients with the primary site in the fundus ( HR = 1.74, 95% CI: 1.62-1.86), gastric body ( HR = 2.03, 95% CI: 1.93-2.14), gastric antrum ( HR = 2.13, 95% CI: 2.04-2.23), pylorus ( HR = 2.28, 95% CI: 2.11-2.47), lesser curvature ( HR = 1.76, 95% CI: 1.67-1.86), and greater curvature ( HR = 1.64, 95% CI: 1.53-1.76) were all higher than those of patients with primary site in the cardia (all P < 0.001). The results of subgroup multivariate Fine-Gray model analysis showed that there were no statistically significant differences in the 10-year death risk of gastric cancer between gastric cancer patients with other primary sites and patients with primary site in the cardia in the age group under 30 years (gastric fundus, gastric body, gastric antrum, lesser curvature, greater curvature), the black group (gastric fundus and lesser curvature) and other races group (gastric fundus, greater curvature and lesser curvature)(all P > 0.05); the results of other subgroups were the same as those of the entire population, namely, the 10-year risk of death from gastric cancer in patients with primary site in the cardia was lower than that in patients without primary site in the cardia (all HR > 1, P < 0.05). Conclusions:In SEER database, the patients with primary site in the cardia has a lower risk of death from gastric cancer compared to those with other primary sites.

Asthma is a chronic inflammatory disease of the airway involving various cellular players. Among the different phenotypes of asthma, neutrophilic asthma is often associated with severe airway inflammation and a notable resistance to corticosteroid treatment. Macrophages, as innate immune cells, play a crucial role in the pathogenesis of neutrophilic asthma. They regulate neutrophil recruitment and activation to promote the progression of airway inflammation. During this process, macrophages also undergo changes in aspects such as efferocytosis. We reviewed the recent research progresses regarding the role of macrophages in the pathogenesis of neutrophilic asthma, aiming to provide valuable insights for future studies in this area.
Humans ; Asthma/pathology* ; Neutrophils/pathology* ; Macrophages/immunology* ; Animals ; Phagocytosis

Objective:To investigate the prognostic value and safety of thoracic radiotherapy in patients with synchronous oligometastatic, driver gene-negative non-small cell lung cancer (NSCLC) receiving immune checkpoint inhibitors (ICIs) as first-line treatment.Methods:Data were retrospectively collected from 55 patients diagnosed with synchronous oligometastatic, driver gene-negative NSCLC who received first-line ICIs from January 2017 to March 2022. These patients were categorized into two groups based on the administration of thoracic radiotherapy: the thoracic radiotherapy group ( n = 27) and the non-thoracic radiotherapy group ( n = 28). Comparative analyses were conducted to evaluate survival outcomes and safety profiles between the two groups. Results:Among the 55 patients, 27 (49.1%) received thoracic radiotherapy. The median follow-up time was 37.0 months (2.2-76.7 months). Patients in the thoracic radiotherapy group exhibited significantly improved median overall survival (OS: 53.4 vs. 21.3 months, P = 0.049) and median progression-free survival (PFS: 13.6 vs. 8.3 months, χ2=4.11, P = 0.043) compared to those in the non-thoracic radiotherapy group. Multivariate Cox regression analysis identified thoracic radiotherapy as an independent prognostic factor for OS ( HR = 0.39, 95% CI: 0.17-0.90, P = 0.027) and PFS ( HR = 0.53, 95% CI: 0.28-0.99, P = 0.046). The most common grade 3 or higher toxicity was bone marrow suppression, occurring in seven patients (12.7%). There was no significant difference between both groups in the incidence of grade 3 or higher treatment-related adverse events, including pneumonitis. Conclusion:In patients with driver gene-negative, synchronous oligometastatic NSCLC, first-line immunotherapy combined with thoracic radiotherapy may improve survival outcomes without increasing the incidence of severe treatment-related adverse events. Further large-scale, randomized prospective trials are needed to verify the findings of this study.

Objective:To investigate the death risk of gastric cancer patients with different primary sites.Methods:The data of 35 263 gastric cancer patients from 2004 to 2015 were extracted from of the National Cancer Institute the Surveillance, Epidemiology, and End Results (SEER) database. According to the recorded causes of death, the treatment outcomes were classified into 3 categories: death from gastric cancer, death from non-gastric cancer and others. All included patients were grouped by age, gender, race, region, and marital status. Statistical analysis was conducted by using R 4.2.1 software to compare the composition of patients with different treatment outcomes at 3-year, 5-year, and 10-year in each factor subgroup. Univariate Fine-Gray competing model was used to analyze the cumulative incidence of death at 3-year, 5-year, and 10-year in gastric cancer patients with different primary sites. The 5 factors mentioned above were included in the multivariate Fine-Gray competing model to analyze the factors influencing the risk of death from gastric cancer in the entire population at 3-year, 5-year, and 10-year and in gastric cancer patients with different primary sites for 10 years in each factor subgroup after adjusting for demographic differences.Results:Among the entire population, there were 13 392 cases of cardia, 2 198 cases of gastric fundus, 4 510 cases of gastric body, 8 394 cases of antrum, 1 154 cases of pylorus, 3 633 cases of lesser curvature, and 1,982 cases of greater curvature. There were statistically significant differences in the composition of 3-year, 5-year, and 10-year treatment outcomes including death from gastric cancer, non-gastric cancer and other outcomes of gastric cancer patients stratified by different age, gender, race, region, marital status, and primary sites of tumors among subgroups (all P < 0.001). Univariate Fine-Gray model analysis showed that the cumulative incidence of death from gastric cancer was 29.0%, 30.9% and 31.6%, respectively at 3-year,5-year and 10-year after the confirmed diagnosis in gastric cancer patients with primary sites in the cardia, which was all lower than that in those with primary site in the gastric fundus (44.5%, 46.8%, 47.7%), the gastric body (49.1%, 46.8%, 53.5%), the antrum (51.4%, 54.7%, 56.1%), the pylorus (53.6%, 57.8%, 59.8%), the lesser curvature (44.4%, 48.4%, 50.0%), and the greater curvature (42.4%, 45.0%, 46.4%). Multivariate Fine-Gray model analysis showed that the 3-year, 5-year, and 10-year mortality risks of gastric cancer patients with the primary site in the cardia were all lower than those of patients with the primary sites in other locations (all HR > 1, P < 0.001); taking the 10-year death from gastric cancer as an example, the death risks of gastric cancer patients with the primary site in the fundus ( HR = 1.74, 95% CI: 1.62-1.86), gastric body ( HR = 2.03, 95% CI: 1.93-2.14), gastric antrum ( HR = 2.13, 95% CI: 2.04-2.23), pylorus ( HR = 2.28, 95% CI: 2.11-2.47), lesser curvature ( HR = 1.76, 95% CI: 1.67-1.86), and greater curvature ( HR = 1.64, 95% CI: 1.53-1.76) were all higher than those of patients with primary site in the cardia (all P < 0.001). The results of subgroup multivariate Fine-Gray model analysis showed that there were no statistically significant differences in the 10-year death risk of gastric cancer between gastric cancer patients with other primary sites and patients with primary site in the cardia in the age group under 30 years (gastric fundus, gastric body, gastric antrum, lesser curvature, greater curvature), the black group (gastric fundus and lesser curvature) and other races group (gastric fundus, greater curvature and lesser curvature)(all P > 0.05); the results of other subgroups were the same as those of the entire population, namely, the 10-year risk of death from gastric cancer in patients with primary site in the cardia was lower than that in patients without primary site in the cardia (all HR > 1, P < 0.05). Conclusions:In SEER database, the patients with primary site in the cardia has a lower risk of death from gastric cancer compared to those with other primary sites.

Objective To investigate the factors influencing the pregnancy outcomes during frozen-thawed embryo transfer(FET)cycles in patients with polycystic ovary syndrome(PCOS).Methods A retrospective analysis was conducted on patients'data from 882 FET cycles.According to the pregnancy outcome,the patients were divided into non-implantation group(Group A),abortion group(Group B1)and live birth group(Group B2).Clinical data and laboratory parameters were compared among the three groups,and ordered Logistic regression analysis was used to study the factors influencing pregnancy outcomes after FET.Patients were also divided into four groups(C1-C4)based on the number of high-quality embryos obtained(0-3,4-6,7-10,≥11),and their clinical data and laboratory parameters were compared.Results The clinical pregnancy rate,live birth rate,and miscar-riage rate in the 882 treatment cycles were 71.09%(627/882),61.68%(544/882),and 13.24%(83/627),respectively.Single-factor analysis showed significant differences in body mass index(BMI),infertility type,hu-man chorionic gonadotropin(hCG)day estradiol(E2)level,number of retrieved oocytes,and number of high-quality embryos among Groups A,B1,and B2(P<0.05).Further multiple Logistic regression analysis revealed that BMI(OR=1.046,95%CI:1.001-1.093,P=0.044)and a history of previous pregnancy(OR=1.417,95%CI:1.030-1.950,P=0.032)were independent risk factors for successful FET in PCOS patients,while an in-creased number of high-quality embryos was an independent protective factor for successful pregnancy.Based on the results of Group B2,compared to Group A,OR=0.920,95%CI:0.880-0.962,P=0.000;compared to Group B1,OR=0.923,95%CI:0.862-0.988,P=0.022.Compared with the other three groups(C1-C3),the total amount of gonadotropin(Gn)in the C4 group was the lowest and the number of oocytes obtained was the high-est(P<0.05).Multiple comparisons showed that Group C4 had lower BMI,follicle-stimulating hormone(FSH),very low-density lipoprotein(vLDL)levels,a higher luteinizing hormone and follicle-stimulating hormone(LH/FSH)ratio compared to Group C1(P<0.05).Group C4 had lower fasting insulin(FINS)and homeostasis model assessment of insulin resistance(HOMA-IR)levels compared to Group C3,and higher high-density lipoprotein-cholesterol(HDL-C)and apolipoprotein A1(Apo A1)levels compared to Groups C2 and C3(P<0.05).Con-clusion BMI,the history of previous pregnancy and the number of high-quality embryos were both independent factors for predicting pregnancy outcomes in PCOS patients undergoing FET cycles.Patients with a higher number of high-quality embryos have a higher clinical pregnancy rate during FET cycles.

Objective To explore the influencing factors of ecological momentary assessment(EMA)in the implementation of home rehabilitation exercise for middle-aged stroke patients,and to provide a basis for decision-making and practice of precision rehabilitation nursing for stroke.Methods This descriptive qualitative research utilized purposive sampling method to select 8 medical staff,4 information technicians,8 middle-aged stroke patients,and 5 caregivers from a tertiary A general hospital in Wuhan from January 2 to March 10,2024 as the research subjects.Semi-structured interview was conducted based on the framework of diffusion of innovations theory.The data were analyzed using directed content analysis.Results 5 themes and 10 sub-themes were extracted,including relative advantage factors(conducive to precise and dynamic evaluation of patient rehabilitation behavior and symptom trajectory by medical staff;enhancing patient self-management awareness,effectively reducing care burden),compatibility factors(new methods conflict with existing values;new methods are in line with clinical work practice),complexity factors(evaluation frequency affects the accuracy of rehabilitation tracking;limited limb function and social support increase user burden),experimental factors(pilot and real-time feedback improve user experience;experience summary and promotion,the strengthening of practical verification orientation),and observable factors(successful cases of mobile health help popularize new methods;visualization of new methods to enrich mobile health practice).Conclusion There are certain promoting and hindering factors in the implementation of EMA in the field of home rehabilitation exercise for middle-aged stroke patients.In the future,it is necessary to explore the potential of EMA in the field of precision rehabilitation and ensure its compatibility with clinical practice.

Objective:To synthesize the findings of qualitative research on the treatment experience of cancer patients receiving immune checkpoint inhibitors therapy to provide a basis for developing relevant health education strategies and other supportive care interventions.Methods:Qualitative research on the treatment experience of cancer patients receiving immune checkpoint inhibitors therapy, published by May 2022, were searched in English and Chinese databases, including Cochrane Library, PubMed, Embase, PsycINFO, CINAHL, Web of Science, CNKI, Wanfang, VIP, and CBM. The quality of the included studies was evaluated by Joanna Briggs Institute Critical Appraisal Tool for qualitative studies. The research results were summarized and Meta-synthesis using the pooled integration method.Results:A total of 13 articles were included and 62 findings were grouped into 12 new categories according to their similarities. These 12 categories resulted in 4 synthesized findings: life was affected, facing multiple decision scenarios, presence of some unmet needs and gaining positive experiences and personal growth.Conclusions:Although patients experience some positive experiences, a large proportion of them experience significant health distress. Healthcare professionals should develop targeted health education with supportive care strategies on the basis of a comprehensive assessment.

ObjectiveTo explore the mechanism of Buyang Huanwutang in regulating macrophage polarization based on the Toll-like receptor 4 （TLR4） / nuclear factor-κB （NF-κB） / nucleotide-binding oligomerization domain-like receptor 3 （NLRP3） pathway. MethodRAW264.7 macrophages were intervened with lipopolysaccharide （LPS） of different concentrations （0， 1.25， 2.5， 5， 10， 20， 40， and 80 mg·L^-1） for 24 hours. Cell Counting Kit-8 （CCK-8） assay was used to determine the cell viability of RAW264.7 macrophages. The optimal concentration was chosen to establish an in vitro inflammation model induced by LPS. Cells were divided into a blank group （20% blank serum）， a model group （20% blank serum + 10 mg·L^-1 LPS）， a model control group （20% FBS + 10 mg·L^-1 LPS）， low-， medium-， and high-dose （5%， 10%， and 20%） Buyang Huanwutang-containing serum groups， a high-dose （20%） Buyang Huanwutang combined with NLRP3 inhibitor MCC950 （50 μmol·L^-1） group， a high-dose （20%） Buyang Huanwutang combined with reactive oxygen species （ROS） inhibitor NAC （10 μmol·L^-1） group， and a high-dose （20%） Buyang Huanwutang combined with NF-κB inhibitor PDTC （10 μmol·L^-1） group. Enzyme-linked immunosorbent assay （ELISA） was used to detect the expression of interleukin-1β （IL-1β）， interleukin-18 （IL-18）， and tumor necrosis factor-α （TNF-α） in RAW264.7 macrophages. Flow cytometry was employed to measure ROS levels in macrophages. Western blot was used to determine the protein expression of M1-type macrophage-related factors inducible nitric oxide synthase （iNOS） and TNF-α， M2-type macrophage-related factors arginase-1 （Arg-1） and interleukin-10 （IL-10）， as well as the proteins in the TLR4/NF-κB/NLRP3 pathway. ResultCCK-8 results indicated that under 10 mg·L^-1 LPS stimulation， RAW264.7 macrophages exhibited the highest cell viability （P<0.01）. Compared with the blank group， the model group showed significantly increased levels of IL-1β， IL-18， and TNF-α （P<0.05，P<0.01）， increased ROS expression （P<0.05，P<0.01）， increased protein expression of M1-type macrophage factors iNOS and TNF-α （P<0.01）， decreased protein expression of M2-type macrophage factors Arg-1 and IL-10 （P<0.05，P<0.01）， and upregulated expression levels of TLR4， myeloid differentiation factor 88 （MyD88）， phosphorylated inhibitor of NF-κB （p-IκB）/NF-κB inhibitor （IκB）， phosphorylated NF-κB （p-NF-κB） p65/NF-κB p65， NLRP3， apoptosis-associated speck-like protein containing a CARD （ASC）， and pro-Caspase-1 （P<0.05， P<0.01）. Compared with the model group， all Buyang Huanwutang-treated groups and inhibitor groups significantly reduced levels of IL-1β， IL-18， and TNF-α （P<0.01）， suppressed the expression of inflammatory factors in RAW264.7 macrophages， decreased cellular ROS expression levels （P<0.01）， downregulated M1-type macrophages iNOS and TNF-α protein expression （P<0.01）， upregulated M2-type macrophages Arg-1 and IL-10 protein expression （P<0.01）， and lowered protein expression levels of TLR4， MyD88， p-IκB/IκB， p-NF-κB p65/NF-κB p65， NLRP3， ASC， and pro-Caspase-1 （P<0.05， P<0.01）. ConclusionBuyang Huanwutang can improve macrophage inflammation， potentially by reducing macrophage ROS levels， inhibiting RAW264.7 macrophage polarization， and downregulating the protein expression levels of the TLR4/NF-κB/NLRP3 pathway.

Objective:To summarize the research on the application of online health community-based user personain the field of cancer at home and abroad, so as to provide reference for the related research and application in this field in the future.Methods:Computer search of CNKI, China biomedical literature database, VIP, Wanfang, Web of Science, Embase, MEDLINE, PubMed, CINAHL, Cochrane Library, a total of 10 Chinese and English databases, focused on the relevant research on building user personas based on online health communities in the field of cancer, and the search time limit was from the establishment of the database to April 20, 2022. Literature was screened, data extracted and summarized.Results:Totally 11 literatures were included. The construction process of user persona based on online health community included data collection, tag extraction and persona presentation. The functional diversity and implementation feasibility were showed in the application content in the field of cancer. It can quickly identify the differences in health information needs of cancer patients, provide personalized decision support and nursing services, strengthen health information education, and improve patients′ self-management ability.Conclusions:The integration of user persona and cancer field based on online health community was in the initial exploration stage, and the feasibility and effectiveness of promoting patients′ health behavior were confirmed by existing studies. In the future, it is still necessary to be promoted in the empirical research on its application in clinical practice, so as to lay a foundation for providing targeted patient health management programs in the future.